Palliative Chemotherapy for Recurrent and Metastatic Esophageal Cancer

More than two-thirds of patients diagnosed with esophageal cancer will have unresectable disease. The objective of this article is to review the clinical trials utilizing cytotoxic chemotherapy in patients with recurrent and metastatic esophageal cancer. A computerized (MEDLINE) search was performed...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2007-07, Vol.27 (4C), p.2705-2714
Main Authors: GRUNBERGER, Birgit, RADERER, Markus, SCHMIDINGER, Manuela, HEJNA, Michael
Format: Article
Language:English
Subjects:
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - pathology
Esophagus
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Medical sciences
Neoplasm Metastasis
Neoplasm Recurrence, Local - drug therapy
Palliative Care - methods
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:More than two-thirds of patients diagnosed with esophageal cancer will have unresectable disease. The objective of this article is to review the clinical trials utilizing cytotoxic chemotherapy in patients with recurrent and metastatic esophageal cancer. A computerized (MEDLINE) search was performed to identify papers published on this topic between 1966 and 2007. A total of 96 trials were subsequently identified. Two randomized trials compared palliative chemotherapy with best supportive care in 180 patients with advanced esophageal cancer. Effectiveness and side-effects were evaluated in 49 phase II studies and 3 randomized phase III trials. Combination chemotherapy as compared to monochemotherapy is associated with significantly higher response rates but nevertheless results in similar survival. CF (cisplatin and 5-fluorouracil) currently represents one of the most effective regimens for advanced esophageal cancer, while among the newer combinations, irinotecan or taxane-based regimens have also given promising results. Prognosis for the majority of patients, however, remains poor as increases in survival were moderate at best.
ISSN:0250-7005
1791-7530